<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Vasc Surg Venous Lymphat Disord</journal-id><journal-id journal-id-type="iso-abbrev">J Vasc Surg Venous Lymphat Disord</journal-id><journal-id journal-id-type="pmc-domain-id">4655</journal-id><journal-id journal-id-type="pmc-domain">jvsvld</journal-id><journal-title-group><journal-title>Journal of Vascular Surgery: Venous and Lymphatic Disorders</journal-title></journal-title-group><issn pub-type="ppub">2213-333X</issn><issn pub-type="epub">2213-3348</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12052980</article-id><article-id pub-id-type="pmcid-ver">PMC12052980.1</article-id><article-id pub-id-type="pmcaid">12052980</article-id><article-id pub-id-type="pmcaiid">12052980</article-id><article-id pub-id-type="pmid">40120674</article-id><article-id pub-id-type="doi">10.1016/j.jvsv.2025.102235</article-id><article-id pub-id-type="pii">S2213-333X(25)00070-8</article-id><article-id pub-id-type="publisher-id">102235</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Clinical research study</subject></subj-group></article-categories><title-group><article-title>Systemic exogenous progestins with or without estrogens are associated with decreased rates of venous procedures for varicose veins</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name name-style="western"><surname>Jain</surname><given-names initials="P">Paarth</given-names></name><degrees>BS</degrees><email>paarth.jain@students.jefferson.edu</email><xref rid="aff1" ref-type="aff">a</xref><xref rid="cor1" ref-type="corresp">&#8727;</xref></contrib><contrib contrib-type="author" id="au2"><name name-style="western"><surname>Ostrovsky</surname><given-names initials="A">Adam</given-names></name><degrees>BS</degrees><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au3"><name name-style="western"><surname>DiMuzio</surname><given-names initials="P">Paul</given-names></name><degrees>MD</degrees><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au4"><name name-style="western"><surname>Eraso</surname><given-names initials="L">Luis</given-names></name><degrees>MD</degrees><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au5"><name name-style="western"><surname>Nooromid</surname><given-names initials="M">Michael</given-names></name><degrees>MD</degrees><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au6"><name name-style="western"><surname>Salvatore</surname><given-names initials="D">Dawn</given-names></name><degrees>MD</degrees><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au7"><name name-style="western"><surname>Abai</surname><given-names initials="B">Babak</given-names></name><degrees>MD</degrees><xref rid="aff2" ref-type="aff">b</xref></contrib><aff id="aff1"><label>a</label>Sidney Kimmel Medical College, Thomas Jefferson University Hospital, Philadelphia, PA</aff><aff id="aff2"><label>b</label>Division of Vascular and Endovascular Surgery, Thomas Jefferson University Hospital, Philadelphia, PA</aff><aff id="aff3"><label>c</label>Division of Vascular Medicine, Thomas Jefferson University Hospital, Philadelphia, PA</aff></contrib-group><author-notes><corresp id="cor1"><label>&#8727;</label>Correspondence: Paarth Jain, BS, Sidney Kimmel Medical College, Thomas Jefferson University Hospital, 1025 Walnut St #100, Philadelphia, PA 19103 <email>paarth.jain@students.jefferson.edu</email></corresp></author-notes><pub-date pub-type="collection"><month>7</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>20</day><month>3</month><year>2025</year></pub-date><volume>13</volume><issue>4</issue><issue-id pub-id-type="pmc-issue-id">485862</issue-id><elocation-id>102235</elocation-id><history><date date-type="received"><day>23</day><month>9</month><year>2024</year></date><date date-type="accepted"><day>6</day><month>3</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>20</day><month>03</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>06</day><month>05</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-05-07 07:25:24.250"><day>07</day><month>05</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Author(s)</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract id="abs0010"><sec><title>Objectives</title><p>Risk factors for varicose veins (VVs) such as female sex, pregnancy, and obesity are high estrogen states, yet the role of systemic progestins with or without estrogens (SPEs) in VV management is not well characterized. This study investigates how SPE use affects rates of venous procedures for patients with VV.</p></sec><sec><title>Methods</title><p>The TriNetX database was queried for subjects with <italic toggle="yes">International Classification of Diseases</italic>, 10th edition, diagnoses of asymptomatic VV, chronic venous insufficiency, and complicated VV (inflammation or ulceration). Patients were divided into a control cohort with no subsequent SPE use, a progestin-only cohort, and a combined estrogen-progestin (CEP) cohort. Further stratification by VV symptomology and premenopausal status (age&#160;&lt;40 years) was also performed. Cohorts were one:one propensity matched on known and theorized risk factors for VV including age, race, prior pregnancy, and body mass index. The outcomes of interest were deep vein thrombosis, pregnancy, stab phlebectomy, endovenous ablation, and sclerotherapy.</p></sec><sec><title>Results</title><p>Database query yielded 674,838 controls, 7597 CEP patients, and 13,758 progestin-only patients before matching. After propensity matching, compared with controls, the CEP cohort received fewer stab phlebectomies (relative risk [RR], 0.52; 95% confidence interval [CI], 0.42-0.64; <italic toggle="yes">P</italic>&#160;&lt; .001), endovenous ablations (RR, 0.50; 95% CI, 0.43-0.59; <italic toggle="yes">P</italic>&#160;&lt; .001) or any venous interventions (RR, 0.68; 95% CI, 0.61-0.76; <italic toggle="yes">P</italic>&#160;&lt; .001), with no difference in sclerotherapy (<italic toggle="yes">P</italic>&#160;= .12). Similarly, the progestin-only cohort was less likely to receive stab phlebectomy (RR, 0.37; 95% CI, 0.31-0.43; <italic toggle="yes">P</italic>&#160;&lt; .001), endovenous ablation (RR, 0.35; 95% CI, 0.31-0.40; <italic toggle="yes">P</italic>&#160;&lt; .001), sclerotherapy (RR, 0.65; 95% CI, 0.56-0.75; <italic toggle="yes">P</italic>&#160;&lt; .001), and any venous procedure (RR, 0.57; 95% CI, 0.52-0.62; <italic toggle="yes">P</italic>&#160;&lt; .001). Compared with the progestin-only cohort, the CEP cohort had higher rates of sclerotherapy (RR, 1.38; 95% CI, 1.12-1.72; <italic toggle="yes">P</italic>&#160;= .003) and overall venous procedures (RR, 1.16; 95% CI, 1.00-1.34; <italic toggle="yes">P</italic>&#160;= .048). When possible, analysis stratified by symptomatic status and menopausal status revealed similar findings for subcohorts. Finally, the CEP cohort had lower risk of pregnancy than controls during the first 1200&#160;days of observation, but subsequently had greater risk of pregnancy (RR, 1.38; 95% CI, 1.21-1.57; <italic toggle="yes">P</italic>&#160;&lt; .001). Kaplan-Meier analysis showed that the rates of venous intervention were lower throughout the observation period.</p></sec><sec><title>Conclusions</title><p>This large, population-based cohort study demonstrated that, despite variable risk of deep vein thrombosis and pregnancy for estrogen-progestin and progestin-only treatment cohorts, both SPE formulations were associated with significantly fewer venous procedures for VVs than controls, with progestin-only cohorts undergoing the fewest procedures. This warrants further investigation into the role of SPE in VV disease progression and the utility of systemic progestins as an adjunct therapy for VVs.</p></sec></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>Varicose veins</kwd><kwd>Venous insufficiency</kwd><kwd>Phlebectomy</kwd><kwd>Endovenous ablation</kwd><kwd>Sclerotherapy</kwd><kwd>Women's health</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta><notes><p id="misc0010">From the Society of Vascular Surgery</p></notes></front><body><p id="p0010">
<boxed-text id="dtbox1" position="float" orientation="portrait"><caption><title>Article Highlights</title></caption><p id="p0015">
<list list-type="simple" id="ulist0010"><list-item id="u0010"><label>&#8226;</label><p id="p0020"><bold>Type of Research</bold>: Retrospective cohort study using the TriNetX database</p></list-item><list-item id="u0015"><label>&#8226;</label><p id="p0025"><bold>Key Findings:</bold> Among all women with a diagnosis of varicose veins, the 7206 taking combination estrogen-progestin and the 11,597 taking progestin-only received significantly fewer venous procedures compared with one:one matched controls (relative risk, 0.68; 95% confidence interval, 0.61-0.76 [<italic toggle="yes">P</italic>&#160;&lt; .0001] and relative risk, 0.57, 95% confidence interval, 0.52-0.62 [<italic toggle="yes">P</italic>&#160;&lt; .0001], respectively).</p></list-item><list-item id="u0020"><label>&#8226;</label><p id="p0030"><bold>Take Home Message:</bold> These findings invite collaboration with obstetrics and gynecology to explore the potential of exogenous estrogen and progestin as an adjunct treatment for varicose veins.</p></list-item></list>
</p></boxed-text>
</p><p id="p0035">Varicose veins (VVs) have a lifetime prevalence of &#8804;50% and are responsible for $3 billion in health care spending annually worldwide.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref><sup>,</sup><xref rid="bib2" ref-type="bibr"><sup>2</sup></xref> Beyond the cosmetic importance of treating VVs, inadequately treated pathology can be painful and can lead to skin ulceration.<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref><sup>,</sup><xref rid="bib4" ref-type="bibr"><sup>4</sup></xref> Risk factors for VVs such as female sex, pregnancy, and obesity are all high estrogen states, suggesting that sex hormones such as estrogen and progestin may contribute to the development and progression of venous pathology.<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref></p><p id="p0040">Systemic progestins and/or estrogens (SPE) formulations can either be progestin-only or combined estrogen-progestin (CEP). The role of these medications in the progression of VVs has not been well-studied and is difficult to anticipate. On one hand, they increase rates of circulating progestin and estrogen, increasing risk of venous pathology, whereas on the other hand, they may prevent pregnancy, a known risk factor for VVs. At the cellular level, sex hormones modulate venous inflammation and contribute to vascular remodeling, but the net effect on VVs is unclear.<xref rid="bib6" ref-type="bibr">6</xref>, <xref rid="bib7" ref-type="bibr">7</xref>, <xref rid="bib8" ref-type="bibr">8</xref> This study aimed to assess how SPE use in patients with VVs affects the overall rates of venous procedures between controls with no SHC use, CEP users, and progestin-only users with both asymptomatic and complicated VVs.</p><sec id="sec1"><title>Methods</title><p id="p0045">The study used data from the TriNetX US Collaborative Network (Cambridge, MA), which granted access to data from approximately 112 million patients spanning 63 health care organizations in the United States, including patients with private insurance, Medicare/Medicaid, and no insurance. TriNetX automatically collects and reports data across a patient's entire electronic health record, including patient demographics, diagnoses, procedures, and medications. The TriNetX database has been used previously to conduct both epidemiological and clinical studies relating to vascular surgery and was chosen because it gave the study enormous statistical power, allowed all regions of the United States to be represented, and collected data on pregnancy and SPE use, which are critical to this study.<xref rid="bib9" ref-type="bibr">9</xref>, <xref rid="bib10" ref-type="bibr">10</xref>, <xref rid="bib11" ref-type="bibr">11</xref> Databases specific to vascular surgery, such as the Vascular Quality Initiative, may lack data on pregnancy and SPE use because it is not routinely relevant to the vascular specialist. All patient data were deidentified before collection, use, and transmission; therefore, this study was exempt from institutional review board approval.</p><p id="p0050">A retrospective cohort investigation was conducted between January 1, 2013, and December 31, 2023. Patients aged &#8805;18 years with <italic toggle="yes">International Classification of Diseases</italic>, 10th edition, diagnoses for chronic venous insufficiency, asymptomatic VVs, and VVs with complications (such as inflammation, ulceration, or unspecified complications) were identified (<xref rid="appsec1" ref-type="sec">Supplementary Table</xref>, online only). This population was subdivided into treatment groups based on SPE use after VV diagnosis. This generated a control group without subsequent SPE use, a progestin-only treatment group, and a progestin-estrogen combined hormonal contraception (CEP) treatment group. An estrogen-only cohort was considered but ultimately not included in the investigation owing to a low sample size. The low sample size for estrogen-only therapy was probably because estrogen-only treatment is contraindicated in patients with an intact uterus owing to the risk of uterine cancer.<xref rid="bib40" ref-type="bibr"><sup>12</sup></xref> Patients in treatment groups with an unknown route of hormone administration, nonsystemic administration (eg, topical), or treatment with SPE for&#160;&lt;3 continuous months were excluded. Patients who underwent venous procedures before a diagnosis of VV were also excluded. Patients with first-time SPE use following a venous intervention were assigned to the control cohort. To generate premenopausal cohorts, women aged &gt;40 years or with a diagnosis of menopausal or perimenopausal disorders were excluded. This methodology is in line with prior TriNetX studies identifying premenopausal and postmenopausal patients.<xref rid="bib12" ref-type="bibr"><sup>13</sup></xref><sup>,</sup><xref rid="bib13" ref-type="bibr"><sup>14</sup></xref> To generate asymptomatic VV and complicated VV cohorts, patients were filtered by the appropriate <italic toggle="yes">International Classification of Diseases</italic>, 10th edition, code.</p><p id="p0055">The diagnosis of chronic venous insufficiency, asymptomatic VVs, and complicated VVs served as the index event for the control cohort, and VV diagnosis and subsequent SPE therapy was the index event for treatment groups. Baseline characteristics reflected patient data before the index event, whereas outcomes, by definition, occurred after the index event. To mitigate variances in baseline characteristics across patient groups, propensity-score matching was used with greedy nearest-neighbor matching with a caliper of 0.1 pooled standard deviations. Matching covariates included age, race, systemic hormonal contraception use preceding the diagnosis of VVs, history of pregnancy, tobacco and alcohol consumption, prior deep vein thrombosis (DVT), and body mass index. These factors were selected for their known or theorized influence on the development and progression of VV.<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref><sup>,</sup><xref rid="bib14" ref-type="bibr"><sup>15</sup></xref><sup>,</sup><xref rid="bib15" ref-type="bibr"><sup>16</sup></xref> Laboratory values for endogenous levels of estrogen and progestin were not criteria for matching owing to the rarity of these data for patients in all cohorts. Because TriNetX did not allow manual chart review, data on medication adherence, use of conservative therapy (compression stocking, weight loss, etc), or loss to follow-up after a recommendation for venous procedure could not be assessed.</p><p id="p0060">The outcomes of interest were compared following propensity-matching. The primary outcomes included the proportion of patients who underwent stab phlebectomy, endovenous procedures (radiofrequency, laser, and chemical adhesive), sclerotherapy, and any venous intervention (which counted a patient only once even if they underwent multiple types of procedures). Secondary outcomes of interest included rates of DVT and pregnancy (<xref rid="appsec1" ref-type="sec">Supplementary Table</xref>, online only). Missing data on diagnoses, medications, and outcomes are reported not having said diagnosis, medication, or outcome and TriNetX does not report proportion of variables that are missing on the front end. Categorical and continuous variables were analyzed with &#967;<sup>2</sup> and independent-sample <italic toggle="yes">t</italic> tests, respectively, with <italic toggle="yes">&#945;</italic>&#160;= 0.05. All statistics, including propensity matching, were computed within the TriNetX platform, which uses integrated R, version 3.4.4 (The R Foundation for Statistical Computing, Vienna, Austria), and Python, version 3.6.5 (Python Software Foundation, Centrum voor Wiskunde en Informatica, Amsterdam, the Netherlands).</p></sec><sec id="sec2"><title>Results</title><p id="p0065">A database query yielded 674,838 controls with no SPE after VV diagnosis, 7597 patients with subsequent CEP, and 13,758 patients with subsequent progestin-only therapy after the application of inclusion and exclusion criteria (<xref rid="fig1" ref-type="fig">Fig&#160;1</xref>). The mean follow-up time for the control, CEP, and progestin-only cohorts was 5.5, 6.5, and 6.1&#160;years, respectively. Before propensity score matching, controls were significantly older than the CEP and progestin-only treatment groups (62.6&#160;years vs 48.4 and 48.3 years, respectively; <italic toggle="yes">P</italic>&#160;&lt; .001), White (73% vs 71% vs 67%; <italic toggle="yes">P</italic>&#160;&lt; .001), and Hispanic (28% vs 25% vs 27%; <italic toggle="yes">P</italic>&#160;&lt; .001). Progestin-only cohorts demonstrated significantly higher rates of prior DVT (8% vs 4% for controls; <italic toggle="yes">P</italic>&#160;&lt; .001) and prior pregnancy (21% vs 3% for controls; <italic toggle="yes">P</italic>&#160;&lt; .001). As expected, the CEP cohort was the most likely to have prior CEP use (31% vs 1% for controls; <italic toggle="yes">P</italic>&#160;&lt; .001), and the progestin cohort was most likely to have prior progestin-only use (38% vs 4% for controls; <italic toggle="yes">P</italic>&#160;&lt; .001). Rates of venous procedures before the index event for all cohorts approximated 0%. This ensured that patients in treatment groups did not receive venous procedures during the interval between a VV diagnosis and SPE initiation (<xref rid="tbl1" ref-type="table">Table&#160;I</xref>). These patterns were consistent when stratifying by VV complication status.<fig id="fig1" position="float" orientation="portrait"><label>Fig&#160;1</label><caption><p>Cohort flowchart before propensity matching of any cohort or subcohort. <italic toggle="yes">CEP</italic>, Combined estrogen-progestin; <italic toggle="yes">VV</italic>, varicose veins.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr1.jpg"/></fig><table-wrap position="float" id="tbl1" orientation="portrait"><label>Table&#160;I</label><caption><p>Baseline characteristics for control, combined estrogen-progestin (<italic toggle="yes">CEP</italic>), and progestin-only cohorts containing all women with any varicose vein (VV) diagnosis before matching</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Characteristic</th><th colspan="1" rowspan="1">Control</th><th colspan="1" rowspan="1">CEP</th><th colspan="1" rowspan="1">Progestin</th><th colspan="1" rowspan="1"><italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">No.</td><td colspan="1" rowspan="1">674,838</td><td colspan="1" rowspan="1">7597</td><td colspan="1" rowspan="1">13,758</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Age, years</td><td colspan="1" rowspan="1">62.6&#160;&#177; 16</td><td colspan="1" rowspan="1">48.4&#160;&#177; 19</td><td colspan="1" rowspan="1">48.3&#160;&#177; 17</td><td align="char" colspan="1" rowspan="1">&lt;.0001</td></tr><tr><td colspan="1" rowspan="1">Race: White</td><td align="char" colspan="1" rowspan="1">73</td><td align="char" colspan="1" rowspan="1">71</td><td align="char" colspan="1" rowspan="1">67</td><td align="char" colspan="1" rowspan="1">.007</td></tr><tr><td colspan="1" rowspan="1">Black</td><td align="char" colspan="1" rowspan="1">13</td><td align="char" colspan="1" rowspan="1">12</td><td align="char" colspan="1" rowspan="1">18</td><td align="char" colspan="1" rowspan="1">&lt;.0001</td></tr><tr><td colspan="1" rowspan="1">Asian</td><td align="char" colspan="1" rowspan="1">3</td><td align="char" colspan="1" rowspan="1">3</td><td align="char" colspan="1" rowspan="1">3</td><td align="char" colspan="1" rowspan="1">.272</td></tr><tr><td colspan="1" rowspan="1">Ethnicity: Hispanic</td><td align="char" colspan="1" rowspan="1">28</td><td align="char" colspan="1" rowspan="1">25</td><td align="char" colspan="1" rowspan="1">27</td><td align="char" colspan="1" rowspan="1">&lt;.0001</td></tr><tr><td colspan="1" rowspan="1">DVT</td><td align="char" colspan="1" rowspan="1">4</td><td align="char" colspan="1" rowspan="1">5</td><td align="char" colspan="1" rowspan="1">8</td><td align="char" colspan="1" rowspan="1">&lt;.0001</td></tr><tr><td colspan="1" rowspan="1">Prior pregnancy</td><td align="char" colspan="1" rowspan="1">3</td><td align="char" colspan="1" rowspan="1">14</td><td align="char" colspan="1" rowspan="1">21</td><td align="char" colspan="1" rowspan="1">&lt;.0001</td></tr><tr><td colspan="1" rowspan="1">Tobacco use</td><td align="char" colspan="1" rowspan="1">3</td><td align="char" colspan="1" rowspan="1">6</td><td align="char" colspan="1" rowspan="1">5</td><td align="char" colspan="1" rowspan="1">&lt;.0001</td></tr><tr><td colspan="1" rowspan="1">Alcohol use</td><td align="char" colspan="1" rowspan="1">2</td><td align="char" colspan="1" rowspan="1">3</td><td align="char" colspan="1" rowspan="1">4</td><td align="char" colspan="1" rowspan="1">&lt;.0001</td></tr><tr><td colspan="1" rowspan="1">Prior progestin use</td><td align="char" colspan="1" rowspan="1">4</td><td align="char" colspan="1" rowspan="1">27</td><td align="char" colspan="1" rowspan="1">38</td><td align="char" colspan="1" rowspan="1">&lt;.0001</td></tr><tr><td colspan="1" rowspan="1">Prior CEP use</td><td align="char" colspan="1" rowspan="1">1</td><td align="char" colspan="1" rowspan="1">31</td><td align="char" colspan="1" rowspan="1">7</td><td align="char" colspan="1" rowspan="1">&lt;.0001</td></tr><tr><td colspan="1" rowspan="1">Prior stab phlebectomy</td><td align="char" colspan="1" rowspan="1">0</td><td align="char" colspan="1" rowspan="1">0</td><td align="char" colspan="1" rowspan="1">0</td><td align="char" colspan="1" rowspan="1">&lt;.0001</td></tr><tr><td colspan="1" rowspan="1">Prior endovenous ablation</td><td align="char" colspan="1" rowspan="1">0</td><td align="char" colspan="1" rowspan="1">0</td><td align="char" colspan="1" rowspan="1">0</td><td align="char" colspan="1" rowspan="1">&lt;.0001</td></tr><tr><td colspan="1" rowspan="1">BMI</td><td colspan="1" rowspan="1">31.6&#160;&#177; 8.7</td><td colspan="1" rowspan="1">32.2&#160;&#177; 9.6</td><td colspan="1" rowspan="1">33.5&#160;&#177; 10.5</td><td align="char" colspan="1" rowspan="1">&lt;.0001</td></tr></tbody></table><table-wrap-foot><fn id="tspara0015"><p><italic toggle="yes">BMI,</italic> Body mass index; <italic toggle="yes">DVT,</italic> deep vein thrombosis.</p></fn><fn id="tspara0020"><p>Values are number or mean&#160;&#177; 2 standard deviations.</p></fn></table-wrap-foot></table-wrap></p><p id="p0070">One:one propensity matching generated 7206 patients in the control and CEP cohorts and eliminated the statistically significant differences in age, sex, and relevant comorbidities that existed before matching (<xref rid="tbl2" ref-type="table">Table&#160;II</xref>). When considering all women with any VV diagnosis, there was no significant difference between rates of DVT. The CEP cohort had significantly higher rates of pregnancy (relative risk [RR], 1.38; 95% CI, 1.21-1.57; <italic toggle="yes">P</italic>&#160;&lt; .001). The CEP cohort received fewer stab phlebectomies (RR, 0.52; 95% CI, 0.42-0.64; <italic toggle="yes">P</italic>&#160;&lt; .001), endovenous ablations (RR, 0.50; 95% CI, 0.43-0.59; <italic toggle="yes">P</italic>&#160;&lt; .001), or any venous intervention (RR, 0.48; 95% CI, 0.41-0.56; <italic toggle="yes">P</italic>&#160;&lt; .001); there was no difference in rates of sclerotherapy (RR, 0.87; 95% CI, 0.74-1.04; <italic toggle="yes">P</italic>&#160;= .12). These trends were generally reproduced when stratifying cohorts by complicated VV and asymptomatic VV, and while restricting analysis to pre-menopausal females. One notable exception was that premenopausal women with any type of VVs had no significant difference in rates of stab phlebectomy compared with controls (RR, 0.66; 95% CI, 0.41-1.07; <italic toggle="yes">P</italic>&#160;= .09), but had significantly fewer venous procedures overall (RR, 0.54; 95% CI, 0.42-0.70; <italic toggle="yes">P</italic>&#160;&lt; .001). Another exception was that asymptomatic VV patients on CEP were more likely to undergo sclerotherapy compared with controls (RR, 2.06; <italic toggle="yes">P</italic>&#160;= .01) (<xref rid="tbl3" ref-type="table">Table&#160;III</xref>).<table-wrap position="float" id="tbl2" orientation="portrait"><label>Table&#160;II</label><caption><p>Baseline characteristics of control vs combined estrogen-progestin (<italic toggle="yes">CEP</italic>) patients after 1:1 propensity matching</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Characteristic</th><th colspan="1" rowspan="1">Control</th><th colspan="1" rowspan="1">CEP</th><th colspan="1" rowspan="1"><italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">No.</td><td colspan="1" rowspan="1">7206</td><td colspan="1" rowspan="1">7206</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Age, years</td><td colspan="1" rowspan="1">44.5&#160;&#177; 18.4</td><td colspan="1" rowspan="1">44.5&#160;&#177; 18.6</td><td align="char" colspan="1" rowspan="1">.70</td></tr><tr><td colspan="1" rowspan="1">Race: White</td><td align="char" colspan="1" rowspan="1">70</td><td align="char" colspan="1" rowspan="1">70</td><td align="char" colspan="1" rowspan="1">.47</td></tr><tr><td colspan="1" rowspan="1">Black</td><td align="char" colspan="1" rowspan="1">12</td><td align="char" colspan="1" rowspan="1">12</td><td align="char" colspan="1" rowspan="1">.62</td></tr><tr><td colspan="1" rowspan="1">Asian</td><td align="char" colspan="1" rowspan="1">3</td><td align="char" colspan="1" rowspan="1">3</td><td align="char" colspan="1" rowspan="1">.86</td></tr><tr><td colspan="1" rowspan="1">Ethnicity: Hispanic</td><td align="char" colspan="1" rowspan="1">27</td><td align="char" colspan="1" rowspan="1">28</td><td align="char" colspan="1" rowspan="1">.30</td></tr><tr><td colspan="1" rowspan="1">DVT</td><td align="char" colspan="1" rowspan="1">3</td><td align="char" colspan="1" rowspan="1">3</td><td align="char" colspan="1" rowspan="1">.56</td></tr><tr><td colspan="1" rowspan="1">Prior pregnancy</td><td align="char" colspan="1" rowspan="1">14</td><td align="char" colspan="1" rowspan="1">14</td><td align="char" colspan="1" rowspan="1">.24</td></tr><tr><td colspan="1" rowspan="1">Tobacco use</td><td align="char" colspan="1" rowspan="1">3</td><td align="char" colspan="1" rowspan="1">3</td><td align="char" colspan="1" rowspan="1">.25</td></tr><tr><td colspan="1" rowspan="1">Alcohol use</td><td align="char" colspan="1" rowspan="1">2</td><td align="char" colspan="1" rowspan="1">2</td><td align="char" colspan="1" rowspan="1">.76</td></tr><tr><td colspan="1" rowspan="1">Prior progestin use</td><td align="char" colspan="1" rowspan="1">21</td><td align="char" colspan="1" rowspan="1">20</td><td align="char" colspan="1" rowspan="1">.11</td></tr><tr><td colspan="1" rowspan="1">Prior CEP use</td><td align="char" colspan="1" rowspan="1">31</td><td align="char" colspan="1" rowspan="1">32</td><td align="char" colspan="1" rowspan="1">.74</td></tr><tr><td colspan="1" rowspan="1">Prior stab phlebectomy</td><td align="char" colspan="1" rowspan="1">0</td><td align="char" colspan="1" rowspan="1">0</td><td align="char" colspan="1" rowspan="1">&gt;.999</td></tr><tr><td colspan="1" rowspan="1">Prior endovenous ablation</td><td align="char" colspan="1" rowspan="1">0</td><td align="char" colspan="1" rowspan="1">0</td><td align="char" colspan="1" rowspan="1">&gt;.999</td></tr><tr><td colspan="1" rowspan="1">Prior sclerotherapy</td><td align="char" colspan="1" rowspan="1">0</td><td align="char" colspan="1" rowspan="1">0</td><td align="char" colspan="1" rowspan="1">&gt;.999</td></tr><tr><td colspan="1" rowspan="1">BMI, mean&#160;&#177; 2 SD</td><td colspan="1" rowspan="1">31.3 (8.7)</td><td colspan="1" rowspan="1">32.1 (9.8)</td><td align="char" colspan="1" rowspan="1">&lt;.001</td></tr></tbody></table><table-wrap-foot><fn id="tspara0030"><p><italic toggle="yes">BMI,</italic> Body mass index; <italic toggle="yes">DVT,</italic> deep vein thrombosis; <italic toggle="yes">SD,</italic> standard deviation.</p></fn><fn id="tspara0035"><p>Values are number or mean&#160;&#177; SD.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="tbl3" orientation="portrait"><label>Table&#160;III</label><caption><p>Outcomes for control vs combined estrogen-progestin (<italic toggle="yes">CEP</italic>) cohorts</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Diagnosis</th><th colspan="1" rowspan="1">Subset (n)</th><th colspan="1" rowspan="1">Outcome</th><th colspan="1" rowspan="1">Control</th><th colspan="1" rowspan="1">CEP</th><th colspan="1" rowspan="1">RR (95% CI), <italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">All VV</td><td colspan="1" rowspan="1">All (7206)</td><td colspan="1" rowspan="1">DVT</td><td align="char" colspan="1" rowspan="1">299 (4.1)</td><td align="char" colspan="1" rowspan="1">290 (4.0)</td><td align="char" colspan="1" rowspan="1">0.97 (0.82-1.13), .705</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Pregnancy</td><td align="char" colspan="1" rowspan="1">353 (4.9)</td><td align="char" colspan="1" rowspan="1">486 (6.7)</td><td align="char" colspan="1" rowspan="1">1.38 (1.21-1.57),&#160;&lt;.001</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Stab phlebectomy</td><td align="char" colspan="1" rowspan="1">255 (3.5)</td><td align="char" colspan="1" rowspan="1">133 (1.8)</td><td align="char" colspan="1" rowspan="1">0.52 (0.42-0.64),&#160;&lt;.0001</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Endovenous ablation</td><td align="char" colspan="1" rowspan="1">417 (5.8)</td><td align="char" colspan="1" rowspan="1">209 (2.9)</td><td align="char" colspan="1" rowspan="1">0.50 (0.43-0.59),&#160;&lt;.0001</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Sclerotherapy</td><td align="char" colspan="1" rowspan="1">269 (3.7)</td><td align="char" colspan="1" rowspan="1">235 (3.3)</td><td align="char" colspan="1" rowspan="1">0.87 (0.74-1.04), .12</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Any intervention</td><td align="char" colspan="1" rowspan="1">689 (9.6)</td><td align="char" colspan="1" rowspan="1">470 (6.5)</td><td align="char" colspan="1" rowspan="1">0.68 (0.61-0.76),&#160;&lt;.0001</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Premenopausal (1973)</td><td colspan="1" rowspan="1">DVT</td><td align="char" colspan="1" rowspan="1">41 (2.1)</td><td align="char" colspan="1" rowspan="1">27 (1.4)</td><td align="char" colspan="1" rowspan="1">0.66 (0.41-1.07), .086</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Pregnancy</td><td align="char" colspan="1" rowspan="1">271 (13.7)</td><td align="char" colspan="1" rowspan="1">328 (16.6)</td><td align="char" colspan="1" rowspan="1">1.21 (1.04-1.40), .011</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Stab phlebectomy</td><td align="char" colspan="1" rowspan="1">70 (3.5)</td><td align="char" colspan="1" rowspan="1">56 (2.8)</td><td align="char" colspan="1" rowspan="1">0.80 (0.57-1.13), .205</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Endovenous ablation</td><td align="char" colspan="1" rowspan="1">140 (7.1)</td><td align="char" colspan="1" rowspan="1">75 (3.8)</td><td align="char" colspan="1" rowspan="1">0.54 (0.41-0.70),&#160;&lt;.0001</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Sclerotherapy</td><td align="char" colspan="1" rowspan="1">56 (2.8)</td><td align="char" colspan="1" rowspan="1">71 (3.6)</td><td align="char" colspan="1" rowspan="1">1.27 (0.90-1.79), .18</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Any intervention</td><td align="char" colspan="1" rowspan="1">194 (9.8)</td><td align="char" colspan="1" rowspan="1">153 (7.8)</td><td align="char" colspan="1" rowspan="1">0.79 (0.64-0.97), .02</td></tr><tr><td colspan="1" rowspan="1">Complicated VV</td><td colspan="1" rowspan="1">All (2715)</td><td colspan="1" rowspan="1">DVT</td><td align="char" colspan="1" rowspan="1">105 (3.9)</td><td align="char" colspan="1" rowspan="1">116 (4.3)</td><td align="char" colspan="1" rowspan="1">1.10 (0.85-1.43), .45</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Pregnancy</td><td align="char" colspan="1" rowspan="1">132 (4.9)</td><td align="char" colspan="1" rowspan="1">198 (7.3)</td><td align="char" colspan="1" rowspan="1">1.50 (1.21-1.85), .001</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Stab phlebectomy</td><td align="char" colspan="1" rowspan="1">201 (7.4)</td><td align="char" colspan="1" rowspan="1">95 (3.5)</td><td align="char" colspan="1" rowspan="1">0.47, (0.37-0.60),&#160;&lt;.0001</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Endovenous ablation</td><td align="char" colspan="1" rowspan="1">331 (12.2)</td><td align="char" colspan="1" rowspan="1">147 (5.4)</td><td align="char" colspan="1" rowspan="1">0.44 (0.37-0.54),&#160;&lt;.0001</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Sclerotherapy</td><td align="char" colspan="1" rowspan="1">204 (7.5)</td><td align="char" colspan="1" rowspan="1">183 (6.7)</td><td align="char" colspan="1" rowspan="1">0.90 (0.74-1.09), .27</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Any intervention</td><td align="char" colspan="1" rowspan="1">514 (18.9)</td><td align="char" colspan="1" rowspan="1">376 (13.8)</td><td align="char" colspan="1" rowspan="1">0.73 (0.65-0.83),&#160;&lt;.0001</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Premenopausal (736)</td><td colspan="1" rowspan="1">DVT</td><td align="char" colspan="1" rowspan="1">14 (1.9)</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">N/A</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Pregnancy</td><td align="char" colspan="1" rowspan="1">100 (13.6)</td><td align="char" colspan="1" rowspan="1">128 (17.4)</td><td align="char" colspan="1" rowspan="1">1.28 (1.01-163), .0437</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Stab phlebectomy</td><td align="char" colspan="1" rowspan="1">48 (6.5)</td><td align="char" colspan="1" rowspan="1">43 (5.8)</td><td align="char" colspan="1" rowspan="1">0.90 (0.60-1.33), .588</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Endovenous ablation</td><td align="char" colspan="1" rowspan="1">85 (11.5)</td><td align="char" colspan="1" rowspan="1">57 (7.7)</td><td align="char" colspan="1" rowspan="1">0.67 (0.49-0.92),&#160;&lt;.0001</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Sclerotherapy</td><td align="char" colspan="1" rowspan="1">44 (6.0)</td><td align="char" colspan="1" rowspan="1">54 (7.3)</td><td align="char" colspan="1" rowspan="1">1.22 (0.84-1.80), .30</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Any intervention</td><td align="char" colspan="1" rowspan="1">136 (18.5)</td><td align="char" colspan="1" rowspan="1">117 (15.9)</td><td align="char" colspan="1" rowspan="1">0.86 (0.69-1.08), .19</td></tr><tr><td colspan="1" rowspan="1">Asymptomatic VV</td><td colspan="1" rowspan="1">All (4166)</td><td colspan="1" rowspan="1">DVT</td><td align="char" colspan="1" rowspan="1">176 (4.2)</td><td align="char" colspan="1" rowspan="1">146 (3.5)</td><td align="char" colspan="1" rowspan="1">0.82 (0.67-1.03), .088</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Pregnancy</td><td align="char" colspan="1" rowspan="1">227 (5.4)</td><td align="char" colspan="1" rowspan="1">244 (5.9)</td><td align="char" colspan="1" rowspan="1">1.07 (0.90-1.28), .42</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Stab phlebectomy</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">N/A</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Endovenous ablation</td><td align="char" colspan="1" rowspan="1">22 (0.5)</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">N/A</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Sclerotherapy</td><td align="char" colspan="1" rowspan="1">18 (0.4)</td><td align="char" colspan="1" rowspan="1">37 (0.9)</td><td align="char" colspan="1" rowspan="1">2.06 (1.17-3.60), .01</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Any intervention</td><td align="char" colspan="1" rowspan="1">32 (0.8)</td><td align="char" colspan="1" rowspan="1">45 (1.1)</td><td align="char" colspan="1" rowspan="1">1.48 (0.90-2.21), .14</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Premenopausal (1151)</td><td colspan="1" rowspan="1">DVT</td><td align="char" colspan="1" rowspan="1">24 (2.0)</td><td align="char" colspan="1" rowspan="1">13 (1.1)</td><td align="char" colspan="1" rowspan="1">0.54, (0.28-1.06), .068</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Pregnancy</td><td align="char" colspan="1" rowspan="1">159 (13.8)</td><td align="char" colspan="1" rowspan="1">166 (14.4)</td><td align="char" colspan="1" rowspan="1">1.04 (0.85-1.28), .675</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Stab phlebectomy</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">N/A</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Endovenous ablation</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">N/A</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Sclerotherapy</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">N/A</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Any intervention</td><td align="char" colspan="1" rowspan="1">13 (1.1)</td><td align="char" colspan="1" rowspan="1">13 (1.1)</td><td align="char" colspan="1" rowspan="1">1.00 (0.47-2.15), &gt;.999</td></tr></tbody></table><table-wrap-foot><fn id="tspara0045"><p><italic toggle="yes">CI,</italic> Confidence interval; <italic toggle="yes">DVT,</italic> deep venous thrombosis; <italic toggle="yes">N/A,</italic> not applicable; <italic toggle="yes">RR,</italic> relative risk; <italic toggle="yes">VV,</italic> varicose vein.</p></fn><fn id="tspara0050"><p>Any venous procedure includes either stab phlebectomy, endovenous ablation, or sclerotherapy.</p></fn><fn id="tspara0055"><p>Values are number (%) unless otherwise indicated.</p></fn></table-wrap-foot></table-wrap></p><p id="p0075">Kaplan-Meier analysis demonstrated that women on CEP were more likely to remain pregnancy free than controls for the first 1500&#160;days of observation. Past this period, this cohort had a greater probability of becoming pregnant (RR, 1.38 (1.21-1.57) ; <italic toggle="yes">P</italic>&#160;&lt; .001). The CEP cohort was more likely to remain vascular intervention-free for the entirety of the observation period (<xref rid="fig2" ref-type="fig">Fig&#160;2</xref>).<fig id="fig2" position="float" orientation="portrait"><label>Fig&#160;2</label><caption><p>Kaplan-Meier analysis of procedure-free <bold>(top)</bold> and pregnancy-free <bold>(bottom)</bold> probability for the combined estrogen-progestin (<italic toggle="yes">CEP</italic>) <bold>(blue)</bold> and control <bold>(purple)</bold> cohorts. Colored shading represents the 95% confidence interval.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr2.jpg"/></fig></p><p id="p0080">One:one propensity matching of control and progestin-only cohorts consisting of all female patients with any VV diagnosis resulted in cohorts of 11,597 each. The progestin-only patients were more likely to experience DVT than controls (RR, 1.16; 95% CI, 1.04-1.30; <italic toggle="yes">P</italic>&#160;= .007) and less likely to become pregnant (RR, 0.83; 95% CI, 0.74-0.93; <italic toggle="yes">P</italic>&#160;= .001). The progestin-only cohort was less likely to undergo stab phlebectomy (RR, 0.37; 95% CI, 0.31-0.43; <italic toggle="yes">P</italic>&#160;&lt; .001), endovenous ablation (RR, 0.35; 95% CI, 0.31-0.40; <italic toggle="yes">P</italic>&#160;&lt; .001), sclerotherapy (RR, 0.65; 95% CI, 0.56-0.75; <italic toggle="yes">P</italic>&#160;&lt; .001), and any venous procedure (RR, 0.57; 95% CI, 0.52-0.62; <italic toggle="yes">P</italic>&#160;&lt; .001). Further subdivision by symptomatic status of VVs and premenopausal status demonstrated no difference in DVT incidence between the cohorts, and no difference in incidence of pregnancy for women with complicated VV. Progestin cohorts maintained lower risk of venous procedures regardless of symptom status or menopausal status (<xref rid="tbl4" ref-type="table">Table&#160;IV</xref>).<table-wrap position="float" id="tbl4" orientation="portrait"><label>Table&#160;IV</label><caption><p>Outcomes for control vs progestin-only cohorts</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Diagnosis</th><th colspan="1" rowspan="1">Subset (n)</th><th colspan="1" rowspan="1">Outcome</th><th colspan="1" rowspan="1">Control</th><th colspan="1" rowspan="1">Progestin only</th><th colspan="1" rowspan="1">RR (95% CI), <italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">All VV</td><td colspan="1" rowspan="1">All (11597)</td><td colspan="1" rowspan="1">DVT</td><td align="char" colspan="1" rowspan="1">565 (4.9)</td><td align="char" colspan="1" rowspan="1">657 (5.7)</td><td align="char" colspan="1" rowspan="1">1.16 (1.04-1.30), .0069</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Pregnancy</td><td align="char" colspan="1" rowspan="1">625 (5.4)</td><td align="char" colspan="1" rowspan="1">518 (4.5)</td><td align="char" colspan="1" rowspan="1">0.83 (0.74-0.93), .0012</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Stab phlebectomy</td><td align="char" colspan="1" rowspan="1">547 (4.7)</td><td align="char" colspan="1" rowspan="1">200 (1.7)</td><td align="char" colspan="1" rowspan="1">0.37 (0.31-0.43),&#160;&lt;.0001</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Endovenous ablation</td><td align="char" colspan="1" rowspan="1">817 (7.0)</td><td align="char" colspan="1" rowspan="1">287 (2.5)</td><td align="char" colspan="1" rowspan="1">0.35 (0.31-0.40),&#160;&lt;.0001</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Sclerotherapy</td><td align="char" colspan="1" rowspan="1">432 (3.7)</td><td align="char" colspan="1" rowspan="1">281 (2.4)</td><td align="char" colspan="1" rowspan="1">0.65 (0.56-0.75),&#160;&lt;.0001</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Any intervention</td><td align="char" colspan="1" rowspan="1">1158 (10.0)</td><td align="char" colspan="1" rowspan="1">655 (5.6)</td><td align="char" colspan="1" rowspan="1">0.57 (0.52-0.62),&#160;&lt;.0001</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Premenopausal (2788)</td><td colspan="1" rowspan="1">DVT</td><td align="char" colspan="1" rowspan="1">73 (2.6)</td><td align="char" colspan="1" rowspan="1">94 (3.4)</td><td align="char" colspan="1" rowspan="1">1.29 (0.95-1.74), .099</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Pregnancy</td><td align="char" colspan="1" rowspan="1">418 (15.0)</td><td align="char" colspan="1" rowspan="1">337 (12.1)</td><td align="char" colspan="1" rowspan="1">0.81 (0.71-0.92), .0015</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Stab phlebectomy</td><td align="char" colspan="1" rowspan="1">129 (4.6)</td><td align="char" colspan="1" rowspan="1">60 (2.2)</td><td align="char" colspan="1" rowspan="1">0.47 (0.34-0.63),&#160;&lt;.0001</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Endovenous ablation</td><td align="char" colspan="1" rowspan="1">197 (7.1)</td><td align="char" colspan="1" rowspan="1">77 (2.8)</td><td align="char" colspan="1" rowspan="1">0.39 (0.30-0.51),&#160;&lt;.0001</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Sclerotherapy</td><td align="char" colspan="1" rowspan="1">94 (3.4)</td><td align="char" colspan="1" rowspan="1">57 (2.0)</td><td align="char" colspan="1" rowspan="1">0.61 (0.44-0.84), .003</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Any intervention</td><td align="char" colspan="1" rowspan="1">288 (10.3)</td><td align="char" colspan="1" rowspan="1">159 (5.7)</td><td align="char" colspan="1" rowspan="1">0.55 (0.46-0.67), .0001</td></tr><tr><td colspan="1" rowspan="1">Complicated VV</td><td colspan="1" rowspan="1">All (4741)</td><td colspan="1" rowspan="1">DVT</td><td align="char" colspan="1" rowspan="1">238 (5.0)</td><td align="char" colspan="1" rowspan="1">251 (5.3)</td><td align="char" colspan="1" rowspan="1">1.05 (0.89-1.25), .546</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Pregnancy</td><td align="char" colspan="1" rowspan="1">177 (3.7)</td><td align="char" colspan="1" rowspan="1">186 (3.9)</td><td align="char" colspan="1" rowspan="1">1.05 (0.86-1.29), .63</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Stab phlebectomy</td><td align="char" colspan="1" rowspan="1">405 (8.5)</td><td align="char" colspan="1" rowspan="1">144 (3.0)</td><td align="char" colspan="1" rowspan="1">0.36 (0.30-0.43),&#160;&lt;.0001</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Endovenous ablation</td><td align="char" colspan="1" rowspan="1">680 (14.3)</td><td align="char" colspan="1" rowspan="1">207 (4.4)</td><td align="char" colspan="1" rowspan="1">0.30 (0.26-0.35)&#160;&lt;.0001</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Sclerotherapy</td><td align="char" colspan="1" rowspan="1">368 (7.8)</td><td align="char" colspan="1" rowspan="1">238 (5.0)</td><td align="char" colspan="1" rowspan="1">0.65 (0.55-0.76),&#160;&lt;.0001</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Any intervention</td><td align="char" colspan="1" rowspan="1">942 (19.9)</td><td align="char" colspan="1" rowspan="1">526 (11.1)</td><td align="char" colspan="1" rowspan="1">0.56 (0.51-0.62),&#160;&lt;.0001</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Premenopausal (1147)</td><td colspan="1" rowspan="1">DVT</td><td align="char" colspan="1" rowspan="1">35 (3.1)</td><td align="char" colspan="1" rowspan="1">27 (2.4)</td><td align="char" colspan="1" rowspan="1">0.77 (0.47-1.27) .303</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Pregnancy</td><td align="char" colspan="1" rowspan="1">133 (11.6)</td><td align="char" colspan="1" rowspan="1">128 (11.2)</td><td align="char" colspan="1" rowspan="1">0.96 (0.77-1.21), .74</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Stab phlebectomy</td><td align="char" colspan="1" rowspan="1">109 (9.5)</td><td align="char" colspan="1" rowspan="1">44 (3.8)</td><td align="char" colspan="1" rowspan="1">0.40 (0.29-0.57),&#160;&lt;.0001</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Endovenous ablation</td><td align="char" colspan="1" rowspan="1">167 (14.6)</td><td align="char" colspan="1" rowspan="1">59 (5.1)</td><td align="char" colspan="1" rowspan="1">0.35 (0.27-0.47)&#160;&lt;.0001</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Sclerotherapy</td><td align="char" colspan="1" rowspan="1">77 (6.7)</td><td align="char" colspan="1" rowspan="1">48 (4.2)</td><td align="char" colspan="1" rowspan="1">0.62 (0.44-0.88), .008</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Any intervention</td><td align="char" colspan="1" rowspan="1">227 (19.8)</td><td align="char" colspan="1" rowspan="1">126 (11.0)</td><td align="char" colspan="1" rowspan="1">0.56 (0.45-0.68),&#160;&lt;.0001</td></tr><tr><td colspan="1" rowspan="1">Asymptomatic VV</td><td colspan="1" rowspan="1">All (6469)</td><td colspan="1" rowspan="1">DVT</td><td align="char" colspan="1" rowspan="1">322 (5.0)</td><td align="char" colspan="1" rowspan="1">366 (5.7)</td><td align="char" colspan="1" rowspan="1">1.14 (0.98-1.32) .085</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Pregnancy</td><td align="char" colspan="1" rowspan="1">382 (5.9)</td><td align="char" colspan="1" rowspan="1">297 (4.6)</td><td align="char" colspan="1" rowspan="1">0.78 (0.67-0.90),&#160;&lt;.0001</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Stab phlebectomy</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">N/A</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">endovenous ablation</td><td align="char" colspan="1" rowspan="1">29 (0.4)</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">N/A</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Sclerotherapy</td><td align="char" colspan="1" rowspan="1">51 (0.8)</td><td align="char" colspan="1" rowspan="1">20 (0.3)</td><td align="char" colspan="1" rowspan="1">0.39 (0.23-0.66), .0004</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Any intervention</td><td align="char" colspan="1" rowspan="1">80 (1.2)</td><td align="char" colspan="1" rowspan="1">34 (0.5)</td><td align="char" colspan="1" rowspan="1">0.43 (0.28-0.63),&#160;&lt;.0001</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Premenopausal (1571)</td><td colspan="1" rowspan="1">DVT</td><td align="char" colspan="1" rowspan="1">52 (3.3)</td><td align="char" colspan="1" rowspan="1">61 (3.9)</td><td align="char" colspan="1" rowspan="1">1.17 (0.82-1.69), .389</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Pregnancy</td><td align="char" colspan="1" rowspan="1">270 (17.2)</td><td align="char" colspan="1" rowspan="1">185 (11.8)</td><td align="char" colspan="1" rowspan="1">0.69 (0.58-0.82),&#160;&lt;.0001</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Stab phlebectomy</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">N/A</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Endovenous ablation</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">N/A</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Sclerotherapy</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">N/A</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Any intervention</td><td align="char" colspan="1" rowspan="1">14 (0.9)</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">N/A</td></tr></tbody></table><table-wrap-foot><fn id="tspara0065"><p><italic toggle="yes">CI,</italic> Confidence interval; <italic toggle="yes">DVT,</italic> deep venous thrombosis; <italic toggle="yes">N/A,</italic> not applicable; <italic toggle="yes">RR,</italic> relative risk; <italic toggle="yes">VV,</italic> varicose vein.</p></fn><fn id="tspara0070"><p>Any venous procedure includes either stab phlebectomy, endovenous ablation, or sclerotherapy.</p></fn><fn id="tspara0075"><p>Values are number (%) unless otherwise indicated.</p></fn></table-wrap-foot></table-wrap></p><p id="p0085">Propensity matching progestin-only and CEP patients yielded 5549 women with any VV diagnosis in each cohort. Women on CEP were no more likely to have DVT (RR, 0.88; 95% CI, 0.74-1.04; <italic toggle="yes">P</italic>&#160;= .139), but were more likely to become pregnant (RR, 1.71; 95% CI, 145-2.01; <italic toggle="yes">P</italic>&#160;&lt; .001). There was no significant difference in the rates of stab phlebectomy (RR, 0.92; 95% CI, 0.70-1.20; <italic toggle="yes">P</italic>&#160;= .52) or endovenous ablation (RR, 1.02; 95% CI,.81-1.27; <italic toggle="yes">P</italic>&#160;= .86). The CEP cohort was more likely to undergo sclerotherapy (RR, 1.38; 95% CI, 1.12-1.72; <italic toggle="yes">P</italic>&#160;= .003) and had more procedures overall (RR, 1.16; 95% CI, 1.00-1.34; <italic toggle="yes">P</italic>&#160;= .048). Among women with asymptomatic VV, CEP users were significantly less likely to have DVT (RR, 0.69; 95% CI, 0.55-0.88; <italic toggle="yes">P</italic>&#160;= .003). Differences in the rates of pregnancy and venous intervention were similar when restricting the analysis to asymptomatic or symptomatic VVs (<xref rid="tbl5" ref-type="table">Table&#160;V</xref>).<table-wrap position="float" id="tbl5" orientation="portrait"><label>Table&#160;V</label><caption><p>Outcomes for progestin-only vs combined estrogen-progestin (<italic toggle="yes">CEP</italic>)</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Diagnosis (n)</th><th colspan="1" rowspan="1">Outcome</th><th colspan="1" rowspan="1">Progestin only</th><th colspan="1" rowspan="1">CEP</th><th colspan="1" rowspan="1">RR (95% CI), <italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">All VV (5549)</td><td colspan="1" rowspan="1">DVT</td><td align="char" colspan="1" rowspan="1">261 (4.7)</td><td align="char" colspan="1" rowspan="1">229 (4.1)</td><td align="char" colspan="1" rowspan="1">0.88 (0.74-1.04), .139</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Pregnancy</td><td align="char" colspan="1" rowspan="1">216 (3.9)</td><td align="char" colspan="1" rowspan="1">369 (6.6)</td><td align="char" colspan="1" rowspan="1">1.71 (1.45-2.01),&#160;&lt;.0001</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Stab phlebectomy</td><td align="char" colspan="1" rowspan="1">109 (2.0)</td><td align="char" colspan="1" rowspan="1">100 (1.8)</td><td align="char" colspan="1" rowspan="1">0.92 (0.70-1.20), .523</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Endovenous ablation</td><td align="char" colspan="1" rowspan="1">149 (2.7)</td><td align="char" colspan="1" rowspan="1">152 (2.7)</td><td align="char" colspan="1" rowspan="1">1.02 (0.81-1.27), .861</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Sclerotherapy</td><td align="char" colspan="1" rowspan="1">138 (2.5)</td><td align="char" colspan="1" rowspan="1">191 (3.4)</td><td align="char" colspan="1" rowspan="1">1.38 (1.12-1.72), .003</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Any intervention</td><td align="char" colspan="1" rowspan="1">316 (5.7)</td><td align="char" colspan="1" rowspan="1">366 (6.6)</td><td align="char" colspan="1" rowspan="1">1.16 (1.00-1.34), .048</td></tr><tr><td colspan="1" rowspan="1">Complicated VV (1969)</td><td colspan="1" rowspan="1">DVT</td><td align="char" colspan="1" rowspan="1">82 (4.2)</td><td align="char" colspan="1" rowspan="1">91 (4.6)</td><td align="char" colspan="1" rowspan="1">1.11 (0.83-1.49), .484</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Pregnancy</td><td align="char" colspan="1" rowspan="1">69 (3.5)</td><td align="char" colspan="1" rowspan="1">138 (7.0)</td><td align="char" colspan="1" rowspan="1">2.00 (1.51-2.65),&#160;&lt;.0001</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Stab phlebectomy</td><td align="char" colspan="1" rowspan="1">62 (3.1)</td><td align="char" colspan="1" rowspan="1">67 (3.4)</td><td align="char" colspan="1" rowspan="1">1.08 (0.77-1.52), .654</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Endovenous ablation</td><td align="char" colspan="1" rowspan="1">87 (4.4)</td><td align="char" colspan="1" rowspan="1">107 (5.4)</td><td align="char" colspan="1" rowspan="1">1.23 (0.93-1.62), .141</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Sclerotherapy</td><td align="char" colspan="1" rowspan="1">94 (4.8)</td><td align="char" colspan="1" rowspan="1">127 (6.4)</td><td align="char" colspan="1" rowspan="1">1.35 (1.04-1.75), .02</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Any intervention</td><td align="char" colspan="1" rowspan="1">195 (9.9)</td><td align="char" colspan="1" rowspan="1">239 (12.1)</td><td align="char" colspan="1" rowspan="1">1.23 (1.03-1.47), .03</td></tr><tr><td colspan="1" rowspan="1">Asymptomatic VV (3126)</td><td colspan="1" rowspan="1">DVT</td><td align="char" colspan="1" rowspan="1">160 (5.1)</td><td align="char" colspan="1" rowspan="1">111 (3.6)</td><td align="char" colspan="1" rowspan="1">0.69 (0.55-0.88), .0025</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Pregnancy</td><td align="char" colspan="1" rowspan="1">121 (3.9)</td><td align="char" colspan="1" rowspan="1">178 (5.7)</td><td align="char" colspan="1" rowspan="1">1.47 (1.17-1.84), .0007</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Stab phlebectomy</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">N/A</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Endovenous ablation</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">N/A</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Sclerotherapy</td><td colspan="1" rowspan="1">N/A</td><td align="char" colspan="1" rowspan="1">28 (0.9)</td><td colspan="1" rowspan="1">N/A</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Any intervention</td><td align="char" colspan="1" rowspan="1">19 (0.6)</td><td align="char" colspan="1" rowspan="1">33 (1.1)</td><td align="char" colspan="1" rowspan="1">1.74 (0.99-3.05), .05</td></tr></tbody></table><table-wrap-foot><fn id="tspara0085"><p><italic toggle="yes">CI,</italic> Confidence interval; <italic toggle="yes">DVT,</italic> deep venous thrombosis; <italic toggle="yes">N/A,</italic> not applicable; <italic toggle="yes">RR,</italic> relative risk; <italic toggle="yes">VV,</italic> varicose vein.</p></fn><fn id="tspara0090"><p>Any venous procedure includes either stab phlebectomy, endovenous ablation, or sclerotherapy.</p></fn><fn id="tspara0095"><p>Values are number (%) unless otherwise indicated.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec3"><title>Discussion</title><p id="p0090">Both CEP therapy and progestin-only therapy were associated with decreased overall rates of venous procedures for VVs, with the progestin-only cohort having even lower rates of venous intervention than the CEP cohort. This finding suggests that, with respect to VVs, the potential effect of CEP use may outweigh the increased estrogen exposure and unexpected increased risk of pregnancy compared with controls. These findings were not restricted to only asymptomatic VV, but also complicated VVs, suggesting that SPE therapy was associated with fewer cosmetic and medically necessary procedures, and across all ages of adult women. This study represents the largest retrospective study investigating the association between SPE and venous procedures for VVs.</p><p id="p0095">This observation has been previously described in a small case-control study, in which post-menopausal women on CEP had lower rates of venous ulceration compared with matched controls (odds ratio, 0.29).<xref rid="bib16" ref-type="bibr"><sup>17</sup></xref> A prior population-based study demonstrated that oral contraceptive use had a nonsignificant association with fewer VVs.<xref rid="bib17" ref-type="bibr"><sup>18</sup></xref> In assessing the reason for fewer procedures among SPE users, we consider prevention of pregnancy, socioeconomic differences between cohorts, and direct physiologic effects of hormonal contraception on lower-extremity veins.</p><sec id="sec3.1"><title>Contraceptive effect</title><p id="p0100">Pregnancy is a known risk factor for the development and progression of VVs, as the gravid uterus compresses the inferior vena cava, increasing pressures in the superficial venous system.<xref rid="bib18" ref-type="bibr"><sup>19</sup></xref> It would, therefore, follow that interventions that prevent pregnancy decrease the progression of VVs and need for intervention. As expected, CEP was protective from pregnancy for the first 3 years of observation. This observation verified that an appropriate treatment cohort was created in the TriNetX environment. The initial contraceptive benefit from CEP use supports the purely contraceptive mechanism of its effect on venous procedure rates. Past the 3-year point, women on CEPs had a greater rate of pregnancy than controls, likely owing to regular follow-up with gynecology, increasing the probability of a pregnancy being documented. Additionally, all three cohorts had an average age &gt;40 years when including all women. Therefore, many women were likely prescribed SPE for noncontraceptive indications, such as endometriosis and vasomotor symptoms of menopause.<xref rid="bib19" ref-type="bibr"><sup>20</sup></xref><sup>,</sup><xref rid="bib20" ref-type="bibr"><sup>21</sup></xref> The combination of lower rates of venous procedures, despite higher rates of pregnancy over the long term, age of the cohorts, and low pregnancy rates (&lt;7% in all cohorts), together indicate that contraception alone may not explain the association between SPE use and lower rates of venous procedures.</p></sec><sec id="sec3.2"><title>Socioeconomic considerations</title><p id="p0105">Given that some insurance policies reject over 60% of claims for VV intervention, treatment can be cost prohibitive.<xref rid="bib21" ref-type="bibr"><sup>22</sup></xref> In fact, lower socioeconomic status (SES) is associated with more severe Clinical, Etiological, Anatomical, and Pathophysiological (CEAP) classification at initial patient presentation.<xref rid="bib22" ref-type="bibr"><sup>23</sup></xref><sup>,</sup><xref rid="bib23" ref-type="bibr"><sup>24</sup></xref> Patients from a lower SES are less likely to use family planning methods altogether, and specifically less likely to use oral contraceptives.<xref rid="bib24" ref-type="bibr"><sup>25</sup></xref> This factor theoretically makes the control population more likely to be economically disadvantaged. If SES were the predominant driver in the difference in rates of venous procedures, it would be expected that the control cohort would undergo fewer interventions, but this is the opposite of what was observed. Additionally, the results show similar findings for asymptomatic and complicated VVs. A complicated VV diagnosis requires skin ulceration and inflammation and is therefore CEAP class C4 or higher. Procedures for this class of venous disease are covered by Medicare or Medicaid without a trial of conservative treatment.<xref rid="bib25" ref-type="bibr"><sup>26</sup></xref> This fact decreases the likely likelihood of differences in procedures being driven by cost, uninsurance, medical tourism, or loss to follow-up after conservative treatment.</p></sec><sec id="sec3.3"><title>Physiological effect</title><p id="p0110">The relationship between estrogen, progesterone, and superficial and deep veins is complex. Retrospective clinical studies have demonstrated that higher serum levels of sex hormones and sex hormone binding globulins are associated with an increased risk of developing VVs.<xref rid="bib26" ref-type="bibr"><sup>27</sup></xref><sup>,</sup><xref rid="bib27" ref-type="bibr"><sup>28</sup></xref> Basic science studies have demonstrated that VVs have increased expressivity of estrogen and progesterone receptors compared with healthy vein.<xref rid="bib28" ref-type="bibr"><sup>29</sup></xref><sup>,</sup><xref rid="bib29" ref-type="bibr"><sup>30</sup></xref> Activation of both receptors modulates venous inflammation and remodeling, but neither hormone is clearly protective or pathological from an inflammatory or structural standpoint. Progestin may suppress inflammatory cytokines interleukin-6 and tumor necrosis factor-&#945;, thereby reducing inflammation and increasing vascular tone.<xref rid="bib30" ref-type="bibr"><sup>31</sup></xref> However, progestin may also inhibit matrix metalloproteinase expression, which reduces extracellular matrix degradation and prevents necessary vascular remodeling.<xref rid="bib31" ref-type="bibr"><sup>32</sup></xref> Estrogen receptor activation may reduce inflammation by stabilizing endothelial function and may increase matrix metalloproteinase expression, allowing for extracellular matrix turnover and vascular remodeling.<xref rid="bib32" ref-type="bibr"><sup>33</sup></xref><sup>,</sup><xref rid="bib33" ref-type="bibr"><sup>34</sup></xref> Estrogen may also induce vasodilation via nitric oxide and prostacyclins, which may stabilize the vascular wall, but may also cause the venous dilation that promotes progression of disease.<xref rid="bib34" ref-type="bibr"><sup>35</sup></xref><sup>,</sup><xref rid="bib35" ref-type="bibr"><sup>36</sup></xref> Given this complexity, the basic science does not clearly account for the difference in rates of venous procedures between the control and SPE cohorts, nor the fewer procedures undergone by the progestin-only cohort compared with the CEP cohort. Rather, the association demonstrated in this study may provide some evidence that the net effect of SPE on venous pathology results in fewer procedures, albeit in the setting of the several limitations of this study discussed elsewhere in this article.</p></sec><sec id="sec3.4"><title>DVT risk</title><p id="p0115">It has been well-established that SPE increases the risk of venous thromboembolism, which subsequently increases VV risk.<xref rid="bib36" ref-type="bibr"><sup>37</sup></xref><sup>,</sup><xref rid="bib37" ref-type="bibr"><sup>38</sup></xref> The lower observed incidence of DVT in the CEP cohort may be attributed to a variety of factors. CEPs are prescribed judiciously, particularly for individuals who exhibit known DVT risk factors such as prior DVT, hypercoagulable state, or smoking.<xref rid="bib38" ref-type="bibr"><sup>39</sup></xref><sup>,</sup><xref rid="bib39" ref-type="bibr"><sup>40</sup></xref> As a result, the patient population in the CEP group of this study carries a lower baseline thrombotic risk before CEP initiation. The addition of CEP may not increase thrombotic risk to a degree that supersedes the risk in the control group. Conversely, progestin users were more likely to experience DVT than controls, likely attributable to a higher baseline thrombotic risk, as seen in higher risk of DVT before VV diagnosis (8% progestins vs 5% controls). Although the study design does attempt to match for thrombotic risk by matching for DVT history, the full spectrum of hypercoagulable states, which includes malignancies and genetic conditions, cannot all be matched for. These patients with a higher baseline risk for thrombosis are more likely to be prescribed progestin-only contraception and therefore demonstrate higher rates of DVT.</p></sec><sec id="sec3.5"><title>Limitations</title><p id="p0120">This study has several limitations. It cannot account for the dosage, duration, or changes to systemic hormonal therapy because these data are unavailable in the TriNetX database. Additionally, although race was accounted for, some socioeconomic factors such as insurance status and home address were not available to perform a more robust investigation regarding how access to venous services may be influencing rates of venous procedures. Furthermore, metrics such as the vein location, length of lesion, and degree of venous reflux are unavailable in TriNetX, as is CEAP score for patients' venous disease. Therefore, this study is limited to analyzing procedural data. Fewer procedures do not equate to less progression of disease, because procedure rates may be affected by patient or provider preference, underinsurance, and medical tourism, especially for asymptomatic VV. Using institutional data to add these missing parameters is an opportunity for further research.</p><p id="p0125">Systemic hormonal contraception brings with it thrombotic and metabolic risks that warrant careful evaluation. Therefore, this retrospective, population-based cohort study is not sufficient to advocate for the initiation of SPE in all patients with VVs. However, the data supports that women with VV who are already on SPE may continue it, because it may be a valuable adjunct to the procedural management of their condition.</p></sec></sec><sec id="sec4"><title>Conclusions</title><p id="p0130">This population-based retrospective cohort study demonstrated that both estrogen-progestin combination therapy and progestin-only therapy were associated with decreased rates of venous procedures for both asymptomatic and complicated VVs, possibly secondary to pregnancy prevention and the direct effect of therapy on VVs. This study is hypothesis generating and encourages further investigation of how systemic hormonal therapy affects VV progression. It also offers the opportunity for vascular surgeons to collaborate with colleagues in obstetrics/gynecology to further research the role exogenous progestins and estrogens may play in the future management of VVs.</p></sec><sec id="sec5"><title>Author contributions</title><p id="p0135">Conception and design: PJ, PD, BA</p><p id="p0140">Analysis and interpretation: PJ, AO, PD, LE, MN, DS, BA</p><p id="p0145">Data collection: PJ</p><p id="p0150">Writing the article: PJ, AO, PD</p><p id="p0155">Critical revision of the article: PJ, PD, LE, MN, DS, BA</p><p id="p0160">Final approval of the article: PJ, AO, PD, LE, MN, DS, BA</p><p id="p0165">Statistical analysis: PJ, AO, BA</p><p id="p0170">Obtained funding: Not applicable</p><p id="p0175">Overall responsibility: PJ</p></sec><sec id="sec6"><title>Funding</title><p id="p0180">None.</p></sec><sec sec-type="COI-statement" id="coi0010"><title>Disclosures</title><p id="p0185">None.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name name-style="western"><surname>Ebrahimi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Amanpour</surname><given-names>F.</given-names></name><name name-style="western"><surname>Bolbol Haghighi</surname><given-names>N.</given-names></name></person-group><article-title>Prevalence and risk factors of varicose veins among female hairdressers: a cross sectional study in north-east of Iran</article-title><source>J&#160;Res Health Sci</source><volume>15</volume><year>2015</year><fpage>119</fpage><lpage>123</lpage><pub-id pub-id-type="pmid">26175296</pub-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Png</surname><given-names>C.Y.M.</given-names></name><name name-style="western"><surname>Sumpio</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>DeCarlo</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Dua</surname><given-names>A.</given-names></name></person-group><article-title>Defining the human and health care costs of chronic venous insufficiency</article-title><source>Semin Vasc Surg</source><volume>34</volume><year>2021</year><fpage>59</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">33757637</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.semvascsurg.2021.02.007</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name name-style="western"><surname>Kurz</surname><given-names>X.</given-names></name><name name-style="western"><surname>Lamping</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Kahn</surname><given-names>S.R.</given-names></name><etal/></person-group><article-title>Do varicose veins affect quality of life? Results of an international population-based study</article-title><source>J&#160;Vasc Surg</source><volume>34</volume><year>2001</year><fpage>641</fpage><lpage>648</lpage><pub-id pub-id-type="pmid">11668318</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1067/mva.2001.117333</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name name-style="western"><surname>Mallick</surname><given-names>R.</given-names></name><name name-style="western"><surname>Raju</surname><given-names>A.</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Treatment patterns and outcomes in patients with varicose veins</article-title><source>Am Health Drug Benefits</source><volume>9</volume><year>2016</year><fpage>455</fpage><lpage>465</lpage><pub-id pub-id-type="pmid">28465773</pub-id><pub-id pub-id-type="pmcid">PMC5394556</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name name-style="western"><surname>Aslam</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Muhammad Asif</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ahmad</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Global impact and contributing factors in varicose vein disease development</article-title><source>SAGE Open Med</source><volume>10</volume><year>2022</year><object-id pub-id-type="publisher-id">205031212211189</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/20503121221118992</pub-id><pub-id pub-id-type="pmcid">PMC9425889</pub-id><pub-id pub-id-type="pmid">36051783</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name name-style="western"><surname>Grandi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mueller</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bersinger</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Progestin suppressed inflammation and cell viability of tumor necrosis factor-&#945;-stimulated endometriotic stromal cells</article-title><source>Am J Reprod Immunol</source><volume>76</volume><year>2016</year><fpage>292</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.1111/aji.12552</pub-id><pub-id pub-id-type="pmid">27515307</pub-id></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name name-style="western"><surname>Hermenegildo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Oviedo</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Garc&#237;a-Mart&#237;nez</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Garc&#237;a-P&#233;rez</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Tar&#237;n</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Cano</surname><given-names>A.</given-names></name></person-group><article-title>Progestogens stimulate prostacyclin production by human endothelial cells</article-title><source>Hum Reprod</source><volume>20</volume><year>2005</year><fpage>1554</fpage><lpage>1561</lpage><pub-id pub-id-type="doi">10.1093/humrep/deh803</pub-id><pub-id pub-id-type="pmid">15734756</pub-id></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name name-style="western"><surname>Marinello</surname><given-names>W.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>L.</given-names></name><name name-style="western"><surname>Allen</surname><given-names>T.K.</given-names></name></person-group><article-title>Progestins inhibit Interleukin-1&#946;-Induced matrix metalloproteinase 1 and Interleukin 8 expression via the Glucocorticoid receptor in primary human Amnion Mesenchymal cells</article-title><source>Front Physiol</source><volume>11</volume><year>2020</year><fpage>900</fpage><pub-id pub-id-type="doi">10.3389/fphys.2020.00900</pub-id><pub-id pub-id-type="pmid">32792990</pub-id><pub-id pub-id-type="pmcid">PMC7394241</pub-id></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name name-style="western"><surname>Pham</surname><given-names>A.</given-names></name><name name-style="western"><surname>Heib</surname><given-names>A.</given-names></name><name name-style="western"><surname>Goodman</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Warfarin versus direct oral anticoagulants for patients needing distal deep vein thrombosis treatment</article-title><source>J&#160;Vasc Surg Venous Lymphatic Disord</source><volume>10</volume><year>2022</year><fpage>826</fpage><lpage>831.e1</lpage><pub-id pub-id-type="doi">10.1016/j.jvsv.2022.01.006</pub-id><pub-id pub-id-type="pmid">35124243</pub-id></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name name-style="western"><surname>Patel</surname><given-names>N.</given-names></name><name name-style="western"><surname>Dalmia</surname><given-names>V.K.</given-names></name><name name-style="western"><surname>Carnevale</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lipsitz</surname><given-names>E.</given-names></name><name name-style="western"><surname>Indes</surname><given-names>J.</given-names></name></person-group><article-title>Identification and characterization of new candidates for abdominal aortic aneurysm screening in patients outside of current accepted guidelines</article-title><source>J&#160;Vasc Surg</source><volume>78</volume><year>2023</year><fpage>89</fpage><lpage>95.e2</lpage><pub-id pub-id-type="doi">10.1016/j.jvs.2023.02.017</pub-id><pub-id pub-id-type="pmid">36893948</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name name-style="western"><surname>Jain</surname><given-names>P.</given-names></name><name name-style="western"><surname>DiMuzio</surname><given-names>P.</given-names></name><name name-style="western"><surname>Nooromid</surname><given-names>M.</given-names></name><name name-style="western"><surname>Salvatore</surname><given-names>D.</given-names></name><name name-style="western"><surname>Abai</surname><given-names>B.</given-names></name></person-group><article-title>Trends, risk factors, and outcomes of selective screening for abdominal aortic aneurysms in at-risk patients</article-title><source>J&#160;Vasc Surg</source><volume>81</volume><year>2024</year><fpage>877</fpage><lpage>886.e3</lpage><pub-id pub-id-type="doi">10.1016/j.jvs.2024.12.005</pub-id><pub-id pub-id-type="pmid">39701337</pub-id></element-citation></ref><ref id="bib40"><label>12</label><element-citation publication-type="book" id="optpb7C4y8nkq"><person-group person-group-type="author"><name name-style="western"><surname>Harper-Harrison</surname><given-names>G</given-names></name><name name-style="western"><surname>Carlson</surname><given-names>K</given-names></name><name name-style="western"><surname>Shanahan</surname><given-names>MM</given-names></name></person-group><part-title>Hormone replacement therapy</part-title><source>StatPearls [Internet]</source><year>2024</year><publisher-name>StatPearls Publishing</publisher-name><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK493191/" id="intref0020a">https://www.ncbi.nlm.nih.gov/books/NBK493191/</ext-link><pub-id pub-id-type="pmid">29630243</pub-id></element-citation></ref><ref id="bib12"><label>13</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name name-style="western"><surname>Shih</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>C.Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Lung</surname><given-names>C.C.</given-names></name></person-group><article-title>Menopausal hormone therapy decreases the likelihood of diabetes development in peri-menopausal individuals with prediabetes</article-title><source>Diabetes Metab</source><volume>50</volume><year>2024</year><object-id pub-id-type="publisher-id">101546</object-id><pub-id pub-id-type="doi">10.1016/j.diabet.2024.101546</pub-id><pub-id pub-id-type="pmid">38843591</pub-id></element-citation></ref><ref id="bib13"><label>14</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name name-style="western"><surname>Mackey</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Young</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zimmerer</surname><given-names>R.</given-names></name><name name-style="western"><surname>Miles</surname><given-names>B.</given-names></name></person-group><article-title>Vitamin D deficiency as a risk factor for breast cancer development</article-title><source>J&#160;Clin Oncol</source><volume>41</volume><issue>suppl</issue><year>2023</year><fpage>10559</fpage><pub-id pub-id-type="doi">10.1200/JCO.2023.41.16_suppl.10559</pub-id></element-citation></ref><ref id="bib14"><label>15</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name name-style="western"><surname>Ismail</surname><given-names>L.</given-names></name><name name-style="western"><surname>Normahani</surname><given-names>P.</given-names></name><name name-style="western"><surname>Standfield</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Jaffer</surname><given-names>U.</given-names></name></person-group><article-title>A&#160;systematic review and meta-analysis of the risk for development of varicose veins in women with a history of pregnancy</article-title><source>J&#160;Vasc Surg Venous lymphatic Disord</source><volume>4</volume><year>2016</year><fpage>518</fpage><lpage>524.e1</lpage><pub-id pub-id-type="doi">10.1016/j.jvsv.2016.06.003</pub-id><pub-id pub-id-type="pmid">27639009</pub-id></element-citation></ref><ref id="bib15"><label>16</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name name-style="western"><surname>Carpentier</surname><given-names>P.H.</given-names></name><name name-style="western"><surname>Maricq</surname><given-names>H.R.</given-names></name><name name-style="western"><surname>Biro</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pon&#231;ot-Makinen</surname><given-names>C.O.</given-names></name><name name-style="western"><surname>Franco</surname><given-names>A.</given-names></name></person-group><article-title>Prevalence, risk factors, and clinical patterns of chronic venous disorders of lower limbs: a population-based study in France</article-title><source>J&#160;Vasc Surg</source><volume>40</volume><year>2004</year><fpage>650</fpage><lpage>659</lpage><pub-id pub-id-type="doi">10.1016/j.jvs.2004.07.025</pub-id><pub-id pub-id-type="pmid">15472591</pub-id></element-citation></ref><ref id="bib16"><label>17</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name name-style="western"><surname>B&#233;rard</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kahn</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Abenhaim</surname><given-names>L.</given-names></name></person-group><article-title>Is hormone replacement therapy protective for venous ulcer of the lower limbs?</article-title><source>Pharmacoepidem Drug Safe</source><volume>10</volume><year>2001</year><fpage>245</fpage><lpage>251</lpage><pub-id pub-id-type="doi">10.1002/pds.582</pub-id><pub-id pub-id-type="pmid">11501338</pub-id></element-citation></ref><ref id="bib17"><label>18</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name name-style="western"><surname>Jukkola</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>M&#228;kivaara</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Luukkaala</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hakama</surname><given-names>M.</given-names></name><name name-style="western"><surname>Laurikka</surname><given-names>J.</given-names></name></person-group><article-title>The effects of parity, oral contraceptive use and hormone replacement therapy on the incidence of varicose veins</article-title><source>J&#160;Obstet Gynaecol</source><volume>26</volume><year>2006</year><fpage>448</fpage><lpage>451</lpage><pub-id pub-id-type="doi">10.1080/01443610600747389</pub-id><pub-id pub-id-type="pmid">16846875</pub-id></element-citation></ref><ref id="bib18"><label>19</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name name-style="western"><surname>Sueyoshi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Clevenger</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hart</surname><given-names>E.</given-names></name></person-group><article-title>Large vaginal varicosities in the setting of pregnancy without known hepatic or vascular risks: a case report and review of the Literature</article-title><source>Case Rep Obstet Gynecol</source><volume>2018</volume><year>2018</year><object-id pub-id-type="publisher-id">2394695</object-id><pub-id pub-id-type="doi">10.1155/2018/2394695</pub-id><pub-id pub-id-type="pmcid">PMC5827883</pub-id><pub-id pub-id-type="pmid">29607234</pub-id></element-citation></ref><ref id="bib19"><label>20</label><element-citation publication-type="other" id="sref19"><person-group person-group-type="author"><collab>American College of Obstetricians and Gynecologists (ACOG)</collab></person-group><article-title>Use of hormonal contraception in women with Coexisting medical conditions</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.acog.org/clinical/clinical-guidance/practice-bulletin/articles/2019/06/use-of-hormonal-contraception-in-women-with-coexisting-medical-conditions" id="intref0020">https://www.acog.org/clinical/clinical-guidance/practice-bulletin/articles/2019/06/use-of-hormonal-contraception-in-women-with-coexisting-medical-conditions</ext-link><year>2019</year></element-citation></ref><ref id="bib20"><label>21</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name name-style="western"><surname>Marret</surname><given-names>H.</given-names></name><name name-style="western"><surname>Fauconnier</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chabbert-Buffet</surname><given-names>N.</given-names></name><etal/><collab>CNGOF Coll&#232;ge National des Gyn&#233;cologues et Obst&#233;triciens Fran&#231;ais</collab></person-group><article-title>Clinical practice guidelines on menorrhagia: management of abnormal uterine bleeding before menopause</article-title><source>Eur J Obstet Gynecol Reprod Biol</source><volume>152</volume><year>2010</year><fpage>133</fpage><lpage>137</lpage><pub-id pub-id-type="doi">10.1016/j.ejogrb.2010.07.016</pub-id><pub-id pub-id-type="pmid">20688424</pub-id></element-citation></ref><ref id="bib21"><label>22</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name name-style="western"><surname>Ochoa Chaar</surname><given-names>C.I.</given-names></name><name name-style="western"><surname>Aurshina</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>The effect of commercial insurance policies on outcomes of venous ablation</article-title><source>J&#160;Vasc Surg Venous Lymphat Disord</source><volume>6</volume><year>2018</year><fpage>331</fpage><lpage>337.e1</lpage><pub-id pub-id-type="doi">10.1016/j.jvsv.2017.11.013</pub-id><pub-id pub-id-type="pmid">29661363</pub-id></element-citation></ref><ref id="bib22"><label>23</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name name-style="western"><surname>Natour</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Rteil</surname><given-names>A.</given-names></name><name name-style="western"><surname>Corcoran</surname><given-names>P.</given-names></name><name name-style="western"><surname>Weaver</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ahsan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kabbani</surname><given-names>L.</given-names></name></person-group><article-title>Socioeconomic status and clinical stage of patients presenting for treatment of chronic venous disease</article-title><source>Ann Vasc Surg</source><volume>83</volume><year>2022</year><fpage>305</fpage><lpage>312</lpage><pub-id pub-id-type="doi">10.1016/j.avsg.2021.12.010</pub-id><pub-id pub-id-type="pmid">34954041</pub-id></element-citation></ref><ref id="bib23"><label>24</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name name-style="western"><surname>Kiguchi</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Fallentine</surname><given-names>J.</given-names></name><name name-style="western"><surname>Oh</surname><given-names>J.H.</given-names></name><etal/></person-group><article-title>Race, sex, and socioeconomic disparities affect the clinical stage of patients presenting for treatment of superficial venous disease</article-title><source>J&#160;Vasc Surg Venous Lymphat Disord</source><volume>11</volume><year>2023</year><fpage>897</fpage><lpage>903</lpage><pub-id pub-id-type="doi">10.1016/j.jvsv.2023.06.001</pub-id><pub-id pub-id-type="pmid">37343787</pub-id></element-citation></ref><ref id="bib24"><label>25</label><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name name-style="western"><surname>Dehlendorf</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>M.I.</given-names></name><name name-style="western"><surname>Levy</surname><given-names>K.</given-names></name><name name-style="western"><surname>Borrero</surname><given-names>S.</given-names></name><name name-style="western"><surname>Steinauer</surname><given-names>J.</given-names></name></person-group><article-title>Disparities in family planning</article-title><source>Am J Obstet Gynecol</source><volume>202</volume><year>2010</year><fpage>214</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.1016/j.ajog.2009.08.022</pub-id><pub-id pub-id-type="pmid">20207237</pub-id><pub-id pub-id-type="pmcid">PMC2835625</pub-id></element-citation></ref><ref id="bib25"><label>26</label><element-citation publication-type="other" id="sref25"><person-group person-group-type="author"><collab>Treatment of Chronic</collab></person-group><article-title>Venous insufficiency of the lower extremities. (2020). CMS.gov; the centers for medicare &amp; medicaid services</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdId=38720&amp;ver=6" id="intref0025">https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdId=38720&amp;ver=6</ext-link></element-citation></ref><ref id="bib26"><label>27</label><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name name-style="western"><surname>Ciardullo</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Panico</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bellati</surname><given-names>C.</given-names></name><etal/></person-group><article-title>High endogenous estradiol is associated with increased venous distensibility and clinical evidence of varicose veins in menopausal women</article-title><source>J&#160;Vasc Surg</source><volume>32</volume><year>2000</year><fpage>544</fpage><lpage>549</lpage><pub-id pub-id-type="doi">10.1067/mva.2000.107768</pub-id><pub-id pub-id-type="pmid">10957662</pub-id></element-citation></ref><ref id="bib27"><label>28</label><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name name-style="western"><surname>Fan</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Meng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Nie</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C.</given-names></name></person-group><article-title>Sex hormone-binding globulin exerts sex-related causal effects on lower extremity varicose veins: evidence from gender-stratified Mendelian randomization</article-title><source>Front Endocrinol (Lausanne)</source><volume>14</volume><year>2023</year><object-id pub-id-type="publisher-id">1230955</object-id><pub-id pub-id-type="doi">10.3389/fendo.2023.1230955</pub-id><pub-id pub-id-type="pmcid">PMC10752419</pub-id><pub-id pub-id-type="pmid">38152135</pub-id></element-citation></ref><ref id="bib28"><label>29</label><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name name-style="western"><surname>Garc&#237;a-Honduvilla</surname><given-names>N.</given-names></name><name name-style="western"><surname>As&#250;nsolo</surname><given-names>&#193;.</given-names></name><name name-style="western"><surname>Ortega</surname><given-names>M.A.</given-names></name><etal/></person-group><article-title>Increase and Redistribution of sex hormone receptors in premenopausal women are associated with varicose vein remodelling</article-title><source>Oxid Med Cell Longev</source><volume>2018</volume><year>2018</year><object-id pub-id-type="publisher-id">3974026</object-id><pub-id pub-id-type="doi">10.1155/2018/3974026</pub-id><pub-id pub-id-type="pmcid">PMC6140006</pub-id><pub-id pub-id-type="pmid">30250632</pub-id></element-citation></ref><ref id="bib29"><label>30</label><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name name-style="western"><surname>Mashiah</surname><given-names>A.</given-names></name><name name-style="western"><surname>Berman</surname><given-names>V.</given-names></name><name name-style="western"><surname>Thole</surname><given-names>H.H.</given-names></name><etal/></person-group><article-title>Estrogen and progesterone receptors in normal and varicose saphenous veins</article-title><source>Cardiovasc Surg</source><volume>7</volume><year>1999</year><fpage>327</fpage><lpage>331</lpage><pub-id pub-id-type="doi">10.1016/s0967-2109(98)00132-x</pub-id><pub-id pub-id-type="pmid">10386751</pub-id></element-citation></ref><ref id="bib30"><label>31</label><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name name-style="western"><surname>Stone</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>MacDonald</surname><given-names>M.J.</given-names></name></person-group><article-title>The impacts of endogenous progesterone and exogenous progestin on vascular endothelial cell, and smooth muscle cell function: a narrative review</article-title><source>Vasc Pharmacol</source><volume>152</volume><year>2023</year><fpage>107209</fpage><pub-id pub-id-type="doi">10.1016/j.vph.2023.107209</pub-id><pub-id pub-id-type="pmid">37591444</pub-id></element-citation></ref><ref id="bib31"><label>32</label><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name name-style="western"><surname>Grandas</surname><given-names>O.H.</given-names></name><name name-style="western"><surname>Mountain</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Kirkpatrick</surname><given-names>S.S.</given-names></name><etal/></person-group><article-title>Regulation of vascular smooth muscle cell expression and function of matrix metalloproteinases is mediated by estrogen and progesterone exposure</article-title><source>J&#160;Vasc Surg</source><volume>49</volume><year>2009</year><fpage>185</fpage><lpage>191</lpage><pub-id pub-id-type="doi">10.1016/j.jvs.2008.07.080</pub-id><pub-id pub-id-type="pmid">18829229</pub-id></element-citation></ref><ref id="bib32"><label>33</label><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name name-style="western"><surname>Serra</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gallelli</surname><given-names>L.</given-names></name><name name-style="western"><surname>Perri</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Estrogen receptors and chronic venous disease</article-title><source>Eur J Vasc Endovascr Surg</source><volume>52</volume><year>2016</year><fpage>114</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1016/j.ejvs.2016.04.020</pub-id><pub-id pub-id-type="pmid">27220899</pub-id></element-citation></ref><ref id="bib33"><label>34</label><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name name-style="western"><surname>Cid</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Schnaper</surname><given-names>H.W.</given-names></name><name name-style="western"><surname>Kleinman</surname><given-names>H.K.</given-names></name></person-group><article-title>Estrogens and the vascular endothelium</article-title><source>Ann N Y Acad Sci</source><volume>966</volume><year>2002</year><fpage>143</fpage><lpage>157</lpage><pub-id pub-id-type="doi">10.1111/j.1749-6632.2002.tb04211.x</pub-id><pub-id pub-id-type="pmid">12114268</pub-id></element-citation></ref><ref id="bib34"><label>35</label><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name name-style="western"><surname>Farhat</surname><given-names>M.Y.</given-names></name><name name-style="western"><surname>Lavigne</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Ramwell</surname><given-names>P.W.</given-names></name></person-group><article-title>The vascular protective effects of estrogen</article-title><source>FASEB J</source><volume>10</volume><year>1996</year><fpage>615</fpage><lpage>624</lpage><pub-id pub-id-type="pmid">8621060</pub-id></element-citation></ref><ref id="bib35"><label>36</label><element-citation publication-type="journal" id="sref35"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>M.Y.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>T.</given-names></name><name name-style="western"><surname>Meng</surname><given-names>Q.Y.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.C.</given-names></name></person-group><article-title>Estrogen and estrogen receptor affects MMP2 and MMP9 expression through classical ER pathway and promotes migration of lower venous vascular smooth muscle cells</article-title><source>Eur Rev Med Pharmacol Sci</source><volume>24</volume><year>2020</year><fpage>1460</fpage><lpage>1467</lpage><pub-id pub-id-type="doi">10.26355/eurrev_202002_20205</pub-id><pub-id pub-id-type="pmid">32096196</pub-id></element-citation></ref><ref id="bib36"><label>37</label><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name name-style="western"><surname>Lidegaard</surname><given-names>&#216;.</given-names></name><name name-style="western"><surname>L&#248;kkegaard</surname><given-names>E.</given-names></name><name name-style="western"><surname>Svendsen</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Agger</surname><given-names>C.</given-names></name></person-group><article-title>Hormonal contraception and risk of venous thromboembolism: national follow-up study</article-title><source>BMJ</source><volume>339</volume><year>2009</year><fpage>b2890</fpage><pub-id pub-id-type="doi">10.1136/bmj.b2890</pub-id><pub-id pub-id-type="pmid">19679613</pub-id><pub-id pub-id-type="pmcid">PMC2726928</pub-id></element-citation></ref><ref id="bib37"><label>38</label><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name name-style="western"><surname>Keenan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kerr</surname><given-names>T.</given-names></name><name name-style="western"><surname>Duane</surname><given-names>M.</given-names></name><name name-style="western"><surname>Van Gundy</surname><given-names>K.</given-names></name></person-group><article-title>Systematic review of hormonal contraception and risk of venous thrombosis</article-title><source>Linacre Q</source><volume>85</volume><year>2018</year><fpage>470</fpage><lpage>477</lpage><pub-id pub-id-type="doi">10.1177/0024363918816683</pub-id><pub-id pub-id-type="pmid">32431379</pub-id><pub-id pub-id-type="pmcid">PMC6322116</pub-id></element-citation></ref><ref id="bib38"><label>39</label><element-citation publication-type="other" id="sref38"><person-group person-group-type="author"><collab>Centers for Disease Control and Prevention (CDC)</collab></person-group><article-title>U.S. medical eligibility criteria for contraceptive use</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cdc.gov/reproductivehealth/contraception/mmwr/mec/summary.html" id="intref0030">https://www.cdc.gov/reproductivehealth/contraception/mmwr/mec/summary.html</ext-link><year>2020</year></element-citation></ref><ref id="bib39"><label>40</label><element-citation publication-type="book" id="sref39"><person-group person-group-type="author"><name name-style="western"><surname>Cooper</surname><given-names>D.B.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>P.</given-names></name></person-group><part-title>Oral contraceptive pills</part-title><source>StatPearls [Internet]</source><year>2025</year><publisher-name>StatPearls Publishing</publisher-name><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK430882/" id="intref0020m">https://www.ncbi.nlm.nih.gov/books/NBK430882/</ext-link><pub-id pub-id-type="pmid">28613632</pub-id></element-citation></ref></ref-list><sec id="appsec1"><title>Appendix (online only)</title><p id="p0190">
<supplementary-material content-type="local-data" id="mmc1" position="float" orientation="portrait"><caption><title>Supplementary material</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mmc1.docx" position="float" orientation="portrait"/></supplementary-material>
</p></sec><ack id="ack0010"><p id="p0270a">Publication made possible in part by support from the <funding-source id="gs1">Thomas Jefferson University Open Access Fund</funding-source>.</p></ack><fn-group><fn id="d36e1552"><p id="ntpara0010">Additional material for this article may be found online at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.jvsvenous.org" id="intref0010">www.jvsvenous.org</ext-link>.</p></fn><fn id="d36e1558"><p id="ntpara0015">The editors and reviewers of this article have no relevant financial relationships to disclose per the Journal policy that requires reviewers to decline review of any manuscript for which they may have a conflict of interest.</p></fn><fn id="appsec2"><p>Appendix</p><p id="p0195">Additional material for this article may be found online at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.jvsvenous.org" id="intref0015">www.jvsvenous.org</ext-link>.</p></fn></fn-group></back></article></pmc-articleset>